drugset

drugset / Trial / NCT01805830

Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy

NCT01805830 ↗

Phase 3 Completed 189 enrolled Handok Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

The study design of this trial is double blind, parallel-group, randomized, Placebo controlled study.

Timeline

Start: 2012-05
Primary completion: 2013-05
Completion: 2013-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Teneligliptin	Small molecule	20 mg	Oral

Indications